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OBJECTIVEdTo examine demographic, socioeconomic, and biological risk factors for all-
cause, cardiovascular, and noncardiovascular mortality in patients with type 2 diabetes over
8 years and to construct mortality prediction equations.
RESEARCHDESIGNANDMETHODSdBeginning in 2000, survey and medical record
information was obtained from 8,334 participants in Translating Research Into Action for Di-
abetes (TRIAD), a multicenter prospective observational study of diabetes care in managed care.
The National Death Index was searched annually to obtain data on deaths over an 8-year follow-
up period (2000–2007). Predictors examined included age, sex, race, education, income, smoking,
age at diagnosis of diabetes, duration and treatment of diabetes, BMI, complications, comorbidities,
and medication use.
RESULTSdThere were 1,616 (19%) deaths over the 8-year period. In the most parsimonious
equation, the predictors of all-cause mortality included older age, male sex, white race, lower
income, smoking, insulin treatment, nephropathy, history of dyslipidemia, higher LDL choles-
terol, angina/myocardial infarction/other coronary disease/coronary angioplasty/bypass, conges-
tive heart failure, aspirin, b-blocker, and diuretic use, and higher Charlson Index.
CONCLUSIONSdRisk of death can be predicted in people with type 2 diabetes using simple
demographic, socioeconomic, and biological risk factors with fair reliability. Such prediction
equations are essential for computer simulation models of diabetes progression and may, with
further validation, be useful for patient management.
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In 2007, diabetes was the seventh lead-ing cause of death in the U.S. with.71,000 death certiﬁcates listing dia-
betes as the underlying cause of death (1,2).
Diabetes is reported as the underlying
cause of death on 10–15% of death certif-
icates of decedents with diabetes and is
reported anywhere on the death certiﬁ-
cate for 40% of decedents with diabetes
(3–5). Since a diagnosis of diabetes can-
not be ascertained from death certiﬁcates,
the best way to examine mortality in peo-
ple with diabetes is to use a prospective
observational cohort design and follow
diabetic participants until death. Unfor-
tunately, few such studies have been un-
dertaken in nationally representative
populations of people with diabetes. Al-
though many investigators have assessed
risk factors for cardiovascular mortality,
there are few published prediction mod-
els. Such models are needed to construct
computer models to simulate the progres-
sion of diabetes, and may, with further
validation, be useful for clinical decision
making.
Translating Research Into Action for
Diabetes (TRIAD), which began in 1999,
was a prospective observational study of
people with diabetes enrolled in managed
care health plans in the U.S. The primary
objective of TRIAD was to study how
health plan, provider, and patient char-
acteristics impact the processes and out-
comes of diabetes care. TRIAD enrolled
;12,000 diabetic patients from eight geo-
graphically distinct regions in the U.S.We
previously reported on the demographic,
socioeconomic, and biological risk factors
for 4-year mortality in the TRIAD popu-
lation (6). Since our study was published,
two studies have reported prediction
equations for mortality in patients with
type 2 diabetes. One was performed in
Chinese patients living in Hong Kong
(7). The other was limited to patients ini-
tially prescribed a single oral hypoglyce-
mic agent (8).
The objective of this studywas to assess
longer-term mortality in a large, diverse,
U.S. population with type 2 diabetes and
to create prediction equations for all-cause,
cardiovascular, and noncardiovascular
mortality among people with clinically di-
agnosed type 2 diabetes.
RESEARCH DESIGN AND
METHODS
Study population
TRIAD has been described elsewhere (7).
TRIAD studied a random sample of adults
with diabetes enrolled in 10 health plans
in eight states (Hawaii, California, Texas,
Indiana, Michigan, New York, New Jersey,
and Pennsylvania) that served ;180,000
patients with diabetes. Patients were eligi-
ble to participate if they were at least 18
years old, lived in the community, were
not pregnant, had diabetes for at least
1 year, spoke either English or Spanish,
were continuously enrolled in the health
plan for at least 18 months, used at least
one service during that time, and could
give informed consent. Institutional review
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boards at each participating site approved
the study.
In 2000–2001, we administered a
survey by computer-assisted telephone
interview or in writing by mail. In addi-
tion, centrally trained reviewers used
standardized data collection methods to
abstract medical records. Each year, we
obtained information on TRIAD dece-
dents using National Death Index (NDI)
Plus searches (8). Deaths were veriﬁed by
matching name, date of birth, sex, and
social security number of the decedent
with data supplied by the NDI. The sen-
sitivity of NDI has been shown to range
from 87 to 98% (9). Different combina-
tions of identiﬁers excluding social secu-
rity number (available for ;52% of
participants) correctly identify 83–92%
of decedents and 92–99% of living indi-
viduals, makingNDI an accuratemeans of
ascertaining vital status even without so-
cial security numbers (10).
Vital status was determined for all
TRIAD participants (n = 11,927) through
31 December 2007. We included TRIAD
participants who had both survey and
medical record review data (n = 8,820)
and excluded those with type 1 diabetes
deﬁned as age at diagnosis of diabetes
,30 years and treatment with insulin
only (n = 486), leaving a ﬁnal study pop-
ulation of 8,334. We excluded from the
stratiﬁed analyses one decedent who had
“N/A” listed as the underlying cause of
death. Values for variables from the patient
survey that had ,15% missing, including
age, sex, race/ethnicity, education, income,
duration of diabetes, BMI, and smoking
were imputed using single imputation
with the transcan function in S-PLUS (edi-
tion 6.1; Insightful, Seattle, WA).
Outcome measure and covariates
We used the underlying cause of death
ICD-10 code on the NDI ﬁle to group
causes of death. The categories were as
follows: diabetes (E10–E14), cardiovas-
cular disease (I00–99), cancer (C00–97),
renal failure (N17–19), infection (A00–
B99, J10–18), external (injury-related)
causes (V00–Y89), and all other codes.
We investigated all-cause, cardiovascular
(ICD-10 codes I00–I99 for underlying
cause of death), and noncardiovascular
mortality (all other ICD-10 codes for un-
derlying cause of death). Time to follow-
upwas calculated as interview date to date
of death or date censored (31 December
2007).
We assessed demographic covariates
including age, sex, race/ethnicity, education,
and income. We also assessed age at di-
agnosis of diabetes, duration of diabetes,
treatment of diabetes, and BMI. We as-
sessed clinical variables including smoking,
systolic blood pressure, LDL cholesterol,
hemoglobin A1C, microalbuminuria, and
Charlson Index measured at baseline. The
Charlson Index weights various comorbid
conditions (including dementia, cardio-
vascular disease, chronic obstructive pul-
monary disease, peptic ulcer disease, liver
disease, connective tissue disease, and
cancer) by the strength of their associa-
tions with mortality and was used to
quantify comorbidity burden (11,12).
We assessed history of hypertension, dys-
lipidemia, transient ischemia attack (TIA),
stroke, carotid endarterectomy, angina,
myocardial infarction, other coronary
heart disease, coronary angioplasty, coro-
nary bypass, congestive heart failure, pe-
ripheral vascular disease, peripheral
vascular surgery, retinopathy, nephropa-
thy, and diabetic peripheral neuropathy.
We also assessed use of aspirin, diuretic,
ACE inhibitor, angiotensin receptor
blocker (ARB), b-blocker, calcium chan-
nel blocker, other antihypertensive, statin,
or other anticholesterol medications at
baseline.
Statistical analyses
We described the percent distribution of
categorical variables and the mean 6 SD
of continuous variables. Unadjusted haz-
ard rate ratios (HRs) were constructed us-
ing each variable singularly in three
separate Cox proportional hazards mod-
els predicting all-cause, cardiovascular,
and noncardiovascular mortality. Each
separate model speciﬁed the total alive
population as the reference category.
To simultaneously adjust for covari-
ates predicting mortality, we constructed
fully adjusted Cox proportional hazards
models. Again, all-cause mortality, car-
diovascular mortality, and noncardiovas-
cular mortality, deﬁned by underlying
cause of death, were modeled separately,
using the total alive population as the
reference category. We excluded age at
diagnosis of diabetes and duration of di-
abetes from the list of potential predictors
because of their high degree of collinearity
with age. Continuous variables were strat-
iﬁed into categories to allow for interpreta-
tion of patterns and to avoid violating the
multiplicative model’s linearity assump-
tion. The Cox proportional hazardsmodels
also included a stratum statement for
health plan/provider group cluster to ac-
count for the clustered study design and
the correlation among participants within
health plans and provider groups.
To obtain the most parsimonious
model (deﬁned as the best prediction
model with the least number of variables),
we used stepwise Cox proportional haz-
ardsmodels tomodel all-cause, cardiovas-
cular, and noncardiovascular mortality
separately, again with each compared
with the total alive population. Variables
that were signiﬁcant at P, 0.05 were en-
tered and remained in the model. No var-
iables were excluded from entry into the
models; however, for some variables that
we had previously categorized (age, BMI,
and Charlson Index), we now entered
them into the models as continuous var-
iables. The signiﬁcance of the variables in
each of the models was assessed by the
Wald x2 test, and we present the estimated
HRs and 95% CIs. We then used logistic
regression to determine the parameter esti-
mates for the 8-year prediction equations
(the last column of Tables 1, 2, and 3). We
tested for overﬁtting using the method of
Harrell et al. (13). A shrinkage estimate
of,0.85 would suggest overﬁtting (13).
The ﬁt of the equations was assessed by
the22 log-likelihood test and theHosmer-
Lemeshow goodness of ﬁt x2 test. We also
assessed the discrimination of the equa-
tions, deﬁned as their ability to correctly
identify those who died, quantiﬁed by the
concordance index (i.e., the c-statistic) (13).
Our ﬁnal three prediction equations pro-
vide estimates of a subject’s likelihood of
dying over 8 years expressed as a probabil-
ity between 0 and 1.0.
We also conducted 10-fold cross-
validation of the prediction models. We
randomly partitioned the data into 10
equal segments and extracted one 10%
segment before the prediction model was
ﬁtted. The model was ﬁtted with the
remaining 90% of the data and we calcu-
lated sensitivity, speciﬁcity, and positive
predictive value (PPV) for the 10% sub-
sample. This process was repeated 10
times until each segment of the data was
used. We report average sensitivity, spec-
iﬁcity, and PPV for each prediction
model. All analyses were performed using
SAS version 9.2 (SAS Institute, Cary, NC).
RESULTSdOf the 8,334 individuals
included in our analyses, 1,616 (19%)
died before 1 January 2008. The average
length of follow-up was 6.2 years. One
percent of decedents were 25–44 years of
age, 22% 45–64 years of age, 65% 65–84
years of age, and 12% $85 years of age.
Fifty-three percent of decedents were
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Table 1dUnadjusted, fully adjusted, and stepwise Cox proportional hazards regression models and ﬁnal equations predicting all-cause
mortality in the TRIAD population adjusted for health plan/provider group cluster (N = 8,334), 2000–2007
Characteristic
Unadjusted HR
(95% CI)
Fully adjusted HR
(95% CI)
Stepwise HR
(95% CI)
Estimated
regression
coefﬁcient
n 1,616 of 8,334 1,100 of 5,982 1,100 of 5,982
Intercept 27.0892
Age (years) 1.05 (1.05–1.06) 0.0687
Age (years) (ref. ,56) * *
$56 to ,68 2.30 (1.95–2.71) 1.79 (1.44–2.23)
$68 5.18 (4.46–6.01) 3.22 (2.55–4.05)
Sex (female, ref. male) 0.75 (0.68–0.83) 0.59 (0.52–0.68) 0.59 (0.52–0.67) 20.6394
Race/ethnicity (ref. non-Hispanic white)
Hispanic 0.70 (0.61–0.81) 0.78 (0.62–0.97) 0.87 (0.70–1.08) 20.1903
African American 0.87 (0.76–0.99) 0.81 (0.66–0.99) 0.85 (0.70–1.05) 20.2353
Asian/Paciﬁc Islander 0.43 (0.36–0.51) 0.71 (0.54–0.92) 0.76 (0.59–0.99) 20.5272
Other 0.69 (0.57–0.83) 0.69 (0.54–0.89) 0.69 (0.53–0.88) 20.4117
Education (ref. college graduate or more) † *
Some high school or less 2.21 (1.86–2.59) 1.36 (1.08–1.71)
High school graduate 1.38 (1.17–1.63) 1.11 (0.89–1.38)
Some college 1.19 (1.00–1.41) 1.08 (0.87–1.34)
Income (ref. .$75,000)
,$15,000 3.56 (2.91–4.37) 1.80 (1.36–2.38) 1.94 (1.49–2.54) 0.8428
$15,000–40,000 2.43 (1.97–2.99) 1.46 (1.12–1.90) 1.53 (1.18–1.97) 0.4601
$40,000–75,000 1.44 (1.14–1.81) 1.20 (0.91–1.58) 1.24 (0.94–1.63) 0.2327
Age at diabetes diagnosis (years) (ref. ,45) * † *
$45 to ,56 1.30 (1.13–1.49)
$56 2.38 (2.10–2.69)
Duration of diabetes (years) (ref. ,5) * † *
$5 to ,10 1.11 (0.96–1.29)
$10 to ,15 1.70 (1.47–1.98)
$15 2.13 (1.86–2.44)
Treatment of diabetes (ref. oral medication only)
Diet or exercise 1.11 (0.92–1.35) 1.33 (1.04–1.69) 1.18 (0.93–1.49) 0.1844
Oral medication plus insulin 1.43 (1.24–1.65) 1.14 (0.95–1.37) 1.26 (1.05–1.50) 0.2858
Insulin only 2.07 (1.83–2.33) 1.24 (1.05–1.46) 1.30 (1.11–1.53) 0.3114
BMI (kg/m2) (ref. $25 to ,30) † *
,25 1.41 (1.23–1.62) 1.13 (0.95–1.36)
$30 to ,35 0.91 (0.80–1.04) 1.06 (0.90–1.24)
$ 35 0.80 (0.70–0.92) 1.00 (0.84–1.20)
Smoking 1.11 (0.98–1.26) 1.47 (1.25–1.73) 1.59 (1.35–1.87) 0.5816
Systolic blood pressure (mmHg) (ref.,130) † *
$130 to ,140 0.91 (0.79–1.05) 0.91 (0.77–1.08)
$140 1.20 (1.07–1.34) 0.92 (0.79–1.06)
LDL cholesterol (mg/dL) (ref. ,100)
$100 to ,130 0.78 (0.68–0.89) 0.97 (0.84–1.12) 0.96 (0.83–1.10) 20.0828
$130 to ,160 0.86 (0.73–1.02) 1.12 (0.93–1.33) 1.08 (0.91–1.29) 0.1752
$160 1.04 (0.85–1.28) 1.41 (1.13–1.75 1.38 (1.11–1.71) 0.3962
HbA1c (%) (ref. ,7) † *
$7 to ,8 0.97 (0.85–1.10) 1.04 (0.89–1.22)
$8 to ,9 0.90 (0.77–1.05) 0.98 (0.81–1.18)
$9 0.79 (0.69–0.91) 1.03 (0.86–1.24)
History of retinopathy 1.64 (1.46–1.84) 1.05 (0.90–1.23) † *
History of nephropathy 1.79 (1.61–2.00) 1.37 (1.16–1.61) 1.31 (1.12–1.53) 0.3207
History of microalbuminuria 0.95 (0.92–1.10) 0.93 (0.76–1.13) † *
History of diabetic peripheral neuropathy 1.67 (1.49–1.88) 0.99 (0.84–1.15) † *
History of hypertension 1.59 (1.41–1.80) 1.03 (0.86–1.24) † *
History of dyslipidemia 0.85 (0.77–0.94) 0.80 (0.68–0.93) 0.83 (0.72–0.94) 20.2581
Continued on p. 1304
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men.Fifty percentwere non-Hispanicwhite,
15% Hispanic, 18% African American,
9% Asian/Paciﬁc Islander, and 8% of
other race/ethnicity (Supplementary Ap-
pendix). The underlying causes of death
were listed as cardiovascular for 40% of
decedents and noncardiovascular for
60% of decedents. The latter causes of
death included cancer (21%), other (16%),
diabetes (13%), infection (5%), renal failure
(3%), and external (injury-related) causes
(2%). In all, 1,107 (69% of the total) had
a cardiovascular cause listed in either part I
or part II of the death certiﬁcate (ICD-1
codes I00–99), and 31% had no cardiovas-
cular causes listed anywhere on the death
certiﬁcate.
The ﬁrst column of Table 1 presents
the unadjusted HRs for all-cause mortal-
ity. The ﬁrst columns of Tables 2 and 3
present the unadjusted HRs for cardiovas-
cular mortality and noncardiovascular
mortality. In unadjusted analyses of all
three outcomes, we found 21 variables
that were signiﬁcantly associated with
higher risk of mortality. They can be cate-
gorized as demographic, anthropometric,
diabetes, microvascular, macrovascular,
medication, and comorbidity related.
The second columns present the fully
adjusted multivariate Cox proportional
hazards models for all-cause (Table 1),
cardiovascular (Table 2), and noncardio-
vascular mortality (Table 3). For all-cause
and cardiovascular mortality, many of the
variables signiﬁcant in unadjusted analy-
ses remained statistically signiﬁcant in the
fully adjusted models. Current smoking
and higher LDL cholesterol became sig-
niﬁcant in both fully adjusted models.
For noncardiovascular mortality, fewer
than half of the variables remained signif-
icant in the fully adjusted model.
The third column presents the most
parsimonious models predicting all-cause
(Table 1), cardiovascular (Table 2), and
noncardiovascular mortality (Table 3). Al-
though we allowed 31 variables to enter
each model, there were only 15 variables
that remained in the all-cause mortality
model, 16 in the cardiovascular mortality
model, and 8 in the noncardiovascular
mortality model. The variables that best
predict all-cause mortality are older age,
male sex, non-Hispanic white race, lower
income, treatment with insulin with or
without oral medication (vs. oral medica-
tion only), current smoking, higher LDL
cholesterol, history of nephropathy, history
of angina, myocardial infarction, other cor-
onary heart disease, coronary angioplasty,
or coronary bypass, history of congestive
heart failure, use of diuretics or b-blockers,
and higher Charlson Index (Table 1). The
22 log-likelihood test was 1311 (P ,
0.0001) with 24 degrees of freedom. The
max-rescaled R2 was 0.30 and the Hosmer-
Lemeshow goodness-of-ﬁt test was 10.29
(P = 0.24) with eight degrees of freedom.
There were six variables that contributed at
least 1% to the explained variance of the
prediction equations. These were older
age, higherCharlson Index,male sex, lower
income, smoking, andhistory of congestive
heart failure (partial R2 = 0.093, 0.032,
0.021, 0.015, 0.011, and 0.011, respec-
tively). The c-statistic was 0.815, and the
shrinkage of the model was 0.99. Based on
the classiﬁcation table derived from the
logistic regression and ROC curve analy-
sis for the all-cause mortality equation,
the probability level that maximized sensi-
tivity and speciﬁcity was 0.185, yielding a
sensitivity of 73%, a speciﬁcity of 73%,
and a PPV of 38%. Using 10-fold cross-
validation, average sensitivity was 75%,
speciﬁcity was 71%, and PPV was 38%.
The variables that predict cardiovas-
cular mortality are older age, male sex,
non-Hispanic white race, lower income,
treatment of diabetes with insulin (6oral
medication), higher BMI, current smok-
ing, higher LDL cholesterol, history of
Table 1dContinued
Characteristic
Unadjusted HR
(95% CI)
Fully adjusted HR
(95% CI)
Stepwise HR
(95% CI)
Estimated
regression
coefﬁcient
History of congestive heart failure 4.22 (3.78–4.71) 1.74 (1.48–2.05) 1.69 (1.43–1.99) 0.6382
History of TIA, stroke, or endarterectomy 2.51 (2.21–2.85) 1.25 (1.06–1.48) † *
History of angina, myocardial infarction,
other coronary heart disease, coronary
angioplasty, or coronary bypass 2.52 (2.28–2.79) 1.26 (1.09–1.46) 1.28 (1.11–1.49) 0.2536
History of peripheral vascular disease
or peripheral vascular surgery 2.69 (2.38–3.04) 1.26 (1.07–1.48) † *
Current medication use
Aspirin 1.28 (1.16–1.42) 0.81 (0.71–0.94) 0.85 (0.74–0.98) 20.2171
ACE inhibitors 1.26 (1.14–1.39) 1.04 (0.90–1.19) † *
ARB 1.14 (0.97–1.33) 1.05 (0.85–1.30) † *
b-Blocker 1.89 (1.70–2.10) 1.18 (1.02–1.36) 1.20 (1.04–1.38) 0.2676
Calcium channel blocker 1.59 (1.43–1.77) 1.10 (0.95–1.27) † *
Other antihypertensive medication 1.80 (1.55–2.10) 1.14 (0.94–1.38) † *
Diuretic 2.28 (2.07–2.52) 1.36 (1.18–1.57) 1.36 (1.18–1.55) 0.3949
Statin 1.14 (1.03–1.26) 1.02 (0.88–1.18) † *
Other anticholesterol medication 1.16 (0.96–1.41) 1.18 (0.93–1.48) † *
Charlson Index 1.18 (1.14–1.22) 0.2377
Charlson Index (ref. ,1) * *
$1 to ,2 0.99 (0.67–1.45) 1.44 (0.85–2.45)
$2 to ,3 1.66 (1.13–2.42) 1.80 (1.06–3.07)
$4 4.41 (3.05–6.39) 2.61 (1.53–4.46)
P = 1(1+e2X), where X = data included in the table; ref., reference. The estimates given in the last column are for calculating the probability of death over 8 years. *Not
included in the model. †Did not enter stepwise regression because P value .0.05. Boldface values represent signiﬁcant at P , 0.05.
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Table 2dUnadjusted, fully adjusted, and stepwise Cox proportional hazards regression models and ﬁnal equations predicting
cardiovascular mortality in the TRIAD population adjusted for health plan/provider group cluster (N = 8,334), 2000–2007
Characteristic
Unadjusted HR
(95% CI)
Fully adjusted HR
(95% CI)
Stepwise HR
(95% CI)
Estimated
regression
coefﬁcient
n 649 of 7,367 448 of 5,330 448 of 5,330
Intercept 29.5686
Age (years) * * 1.08 (1.07–1.09) 0.0872
Age (years) (ref. ,56)
$56 to ,68 2.29 (1.75–3.00) 1.60 (1.12–2.27)
$68 6.46 (5.07–8.23) 3.57 (2.47–5.16)
Sex (female, ref. male) 0.77 (0.66–0.89) 0.58 (0.47–0.72) 0.63 (0.51–0.77) 20.4377
Race/ethnicity (ref. non-Hispanic white) † *
Hispanic 0.61 (0.48–0.78) 0.65 (0.45–0.94)
African American 0.83 (0.67–1.02) 0.78 (0.57–1.08)
Asian/Paciﬁc Islander 0.36 (0.27–0.48) 0.65 (0.42–1.00)
Other 0.70 (0.52–0.93) 0.68 (0.46–1.01)
Education (ref. college graduate or more) † *
Some high school or less 2.26 (1.76–2.90) 1.47 (1.01–2.15)
High school graduate 1.32 (1.01–1.71) 1.18 (0.82–1.69)
Some college 1.25 (0.96–1.63) 1.22 (0.86–1.73)
Income (ref. .$75,000) † *
,$15,000 4.33 (3.08–6.10) 1.81 (1.14–2.86)
$15,000–40,000 3.07 (2.17–4.35) 1.53 (1.00–2.35)
$40,000–75,000 1.67 (1.14–2.45) 1.36 (0.87–2.13)
Age at diabetes diagnosis (years) (ref. ,45) * † *
$45 to ,56 1.30 (1.05–1.61)
$56 2.50 (2.06–3.04)
Duration of diabetes (years) (ref. ,5) * † *
$5 to ,10 1.12 (0.87–1.43)
$10 to ,15 1.99 (1.56–2.52)
$15 2.56 (2.07–3.18)
Treatment of diabetes (ref. oral medication only)
Diet or exercise 0.95 (0.69–1.31) 1.09 (0.71–1.67) 1.07 (0.72–1.59) 0.0477
Oral medication plus insulin 1.57 (1.26–1.95) 1.24 (0.94–1.65) 1.34 (1.02–1.77) 0.4411
Insulin only 2.31 (1.91–2.79) 1.55 (1.19–2.01) 1.56 (1.21–2.00) 0.5160
BMI (kg/m2) * * 1.02 (1.00–1.04) 0.0181
BMI (kg/m2) (ref. $25 to ,30) * *
,25 1.45 (1.17–1.81) 1.15 (0.87–1.54)
$30 to ,35 0.87 (0.71–1.07) 1.03 (0.80–1.34)
$35 0.84 (0.68–1.03) 1.09 (0.82–1.44)
Smoking 0.91 (0.74–1.12) 1.36 (1.02–1.81) 1.67 (1.26–2.20) 0.5620
Systolic blood pressure (mmHg) (ref.,130) † *
$130 to ,140 0.90 (0.72–1.12) 0.75 (0.57–0.99)
$140 1.22 (1.02–1.46) 0.85 (0.68–1.07)
LDL cholesterol (mg/dL) (ref ,100)
$100 to ,130 0.80 (0.65–1.00) 1.06 (0.84–1.34) 1.03 (0.81–1.30) 20.0018
$130 to ,160 0.97 (0.75–1.26) 1.40 (1.06–1.85) 1.34 (1.02–1.76) 0.3971
$160 1.37 (1.02–1.84) 1.92 (1.39–2.65) 1.85 (1.35–2.53) 0.7869
HbA1c (%) (ref. ,7) † *
$7 to ,8 0.86 (0.70–1.06) 0.88 (0.69–1.13)
$8 to ,9 0.83 (0.65–1.05) 0.84 (0.62–1.13)
$9 0.74 (0.60–0.92) 0.98 (0.74–1.29)
History of retinopathy 1.66 (1.38–2.00) 0.97 (0.76–1.25) † *
History of nephropathy 1.85 (1.56–2.21) 1.36 (1.05–1.77) 1.38 (1.08–1.76) 0.2727
History of microalbuminuria 0.95 (0.76–1.20) 1.03 (0.75–1.41) † *
History of diabetic peripheral neuropathy 1.71 (1.43–2.06) 0.98 (0.76–1.25) † *
History of hypertension 1.95 (1.59–2.39) 1.06 (0.79–1.43) † *
Continued on p. 1306
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nephropathy, history of TIA, stroke, or
endarterectomy, history of angina, myo-
cardial infarction, other coronary heart
disease, coronary angioplasty, or coronary
bypass, history of peripheral vascular dis-
ease or peripheral vascular surgery, and
use of diuretics, b-blockers, or other anti-
hypertensive or cholesterol-lowering
medications (Table 2). The 22 log-
likelihood test was 755 (P , 0.0001)
with 20 degrees of freedom. The max-
rescaled R2 was 0.29 and the Hosmer-
Lemeshow goodness-of-ﬁt test was 10.28
(P = 0.25) with eight degrees of freedom.
There were ﬁve variables that contributed
at least 1% to the explained variance of the
prediction equation. These were older age,
history of congestive heart failure, smok-
ing, male sex, and history of stroke (partial
R2 = 0.120, 0.027, 0.018, 0.013, and
0.010, respectively). The c-statistic was
0.840 and shrinkage was 0.97. For the car-
diovascular mortality prediction equation,
the probability level that maximized sensi-
tivity and speciﬁcity was 0.090, yielding a
sensitivity of 73%, a speciﬁcity of 78%,
and a PPV of 24%. Using 10-fold cross-
validation, average sensitivity was 85%,
speciﬁcity was 63%, and PPV was 18%.
The variables that predict noncardio-
vascular mortality are older age, male sex,
lower income, current smoking, history
of nephropathy, history of congestive
heart failure, use of a diuretic, and a
higher Charlson Index (Table 3). The
22 log-likelihood test was 1023 (P ,
0.0001) with 10 degrees of freedom.
The max-rescaled R2 was 0.24 and the
Hosmer-Lemeshow goodness-of-ﬁt test
was 12.63 (P = 0.13) with eight degrees
of freedom. There were seven variables
that contributed at least 1% to the ex-
plained variance of the prediction eq-
uation. These were older age, higher
Charlson Index, male sex, lower income,
history of congestive heart failure, smok-
ing, and use of a diuretic (partial R2 =
0.137, 0.061, 0.026, 0.025, 0.021,
0.016, and 0.014, respectively). The
c-statistic was 0.797 and shrinkage was
0.98. For the noncardiovascular mortality
prediction equation, the probability level
that maximized sensitivity and speciﬁcity
was 0.120, yielding a sensitivity of 75%, a
speciﬁcity of 70%, and a PPV of 26%. Us-
ing 10-fold cross-validation, average sen-
sitivity was 68%, speciﬁcity was 73%, and
PPV was 27%.
CONCLUSIONSdWe described pre-
dictors of mortality over 8 years in an
insured population with diabetes that had
good access to high-quality medical care.
Although cardiovascular disease was the
leading cause of death in this population
(40%), cancer and other diabetes-related
conditions, such as infections and renal
failure, were also listed frequently as the
underlying cause of death. In general, the
predictors of 8-year mortality in fully
adjusted models are similar to predictors
of 4-year mortality in TRIAD, suggesting
that these models are likely generalizable
enough to predict future mortality risk.
Socio-demographic factors including
older age, male sex, white race/ethnicity,
lower income, and smoking are consis-
tently associatedwithmortality. Diabetes-
related variables including older age at
diagnosis, longer duration of diabetes, and
treatment with insulin with or without oral
medications are associated with mortality
in unadjusted models. In fully adjusted
models, only treatment with insulin with
our without oral medications remains a
signiﬁcant risk factor for all-cause and car-
diovascular mortality. As one might expect,
history of nephropathy predicts all-cause,
Table 2dContinued
Characteristic
Unadjusted HR
(95% CI)
Fully adjusted HR
(95% CI)
Stepwise HR
(95% CI)
Estimated
regression
coefﬁcient
History of dyslipidemia 0.87 (0.75–1.02) 0.71 (0.56–0.90) 0.73 (0.59–0.90) 20.4408
History of congestive heart failure 6.68 (5.68–7.86) 2.49 (1.94–3.19) 1.70 (1.13–3.42) 1.1754
History of TIA, stroke, or endarterectomy 3.36 (2.78–4.05) 1.64 (1.27–2.11) 1.74 (1.37–2.20) 0.7366
History of angina, myocardial infarction,
other coronary heart disease, coronary
angioplasty, or coronary bypass 3.72 (3.19–4.33) 1.50 (1.18–1.91) 1.61 (1.28–2.02) 0.5142
History of peripheral vascular disease
or peripheral vascular surgery 3.63 (3.02–4.35) 1.48 (1.15–1.90) 1.54 (1.21–1.95) 0.4208
Current medication use
Aspirin 1.58 (1.35–1.85) 0.86 (0.69–1.08) † *
ACE inhibitors 1.41 (1.21–1.65) 1.09 (0.87–1.36) † *
ARB 1.21 (0.95–1.54) 1.02 (0.72–1.43) † *
b-Blocker 2.52 (2.15–2.95) 1.38 (1.10–1.72) 1.42 (1.15–1.77) 0.4364
Calcium channel blocker 1.60 (1.36–1.89) 1.00 (0.80–1.26) † *
Other antihypertensive medication 2.19 (1.75–2.74) 1.41 (1.06–1.88) 1.35 (1.02–1.79) 0.4083
Diuretic 2.73 (2.34–3.19) 1.50 (1.20–1.88) 1.48 (1.19–1.83) 0.3625
Statin 1.33 (1.14–1.56) 1.12 (0.89–1.42) † *
Other anticholesterol medication 1.32 (0.99–1.76) 1.40 (0.99–1.96) 1.51 (1.08–2.11) 0.5052
Charlson Index * * † *
Charlson Index (ref. ,1) * *
$1 to ,2 0.54 (0.34–0.88) 0.73 (0.37–1.44)
$2 to ,3 0.95 (0.59–1.52) 0.95 (0.48–1.87)
$4 2.88 (1.84–4.52) 1.08 (0.54–2.16)
P = 1(1+e2X), where X = data included in the table; ref., reference. The estimates given in the last column are for calculating the probability of death over 8 years. *Not
included in the model. †Did not enter stepwise regression because P value .0.05. Boldface values represent signiﬁcant at P , 0.05.
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Table 3dUnadjusted, fully adjusted, and stepwise Cox proportional hazards regression models and ﬁnal equations predicting
noncardiovascular mortality in the TRIAD population adjusted for health plan/provider group cluster (N = 8,334), 2000–2007
Characteristic
Unadjusted HR
(95% CI)
Fully adjusted HR
(95% CI)
Stepwise HR
(95% CI)
Estimated
regression
coefﬁcient
n 967 of 7,684 651 of 5,533 651 of 5,533
Intercept 27.2490
Age (years) * * 1.05 (1.04–1.06) 0.0612
Age (years) (ref. ,56) * *
$56 to ,68 2.38 (1.93–2.93) 1.98 (1.50–2.62)
$68 5.10 (4.21–6.17) 3.48 (2.58–4.70)
Sex (female, ref. male) 0.73 (0.64–0.83) 0.55 (0.46–0.66) 0.55 (0.46–0.65) 20.6110
Race/ethnicity (ref. non-Hispanic white) † *
Hispanic 0.74 (0.62–0.89) 0.88 (0.66–1.17)
African American 0.88 (0.74–1.05) 0.79 (0.60–1.03)
Asian/Paciﬁc Islander 0.44 (0.35–0.55) 0.73 (0.53–1.02)
Other 0.67 (0.52–0.85) 0.70 (0.49–0.94)
Education (ref. college graduate or more) † *
Some high school or less 2.34 (1.90–2.88) 1.32 (0.99–1.77)
High school graduate 1.46 (1.18–1.81) 1.09 (0.82–1.44)
Some college 1.16 (0.93–1.45) 0.99 (0.75–1.30)
Income (ref. .$75,000)
,$15,000 3.47 (2.69–4.47) 1.96 (1.38–2.79) 2.11 (1.51–2.95) 0.8679
$15,000–40,000 2.21 (1.70–2.87) 1.52 (1.09–2.12) 1.61 (1.16–2.22) 0.4483
$40,000–75,000 1.33 (1.00–1.78) 1.13 (0.79–1.60) 1.19 (0.84–1.68) 0.1917
Age at diabetes diagnosis (years) (ref. ,45) * † *
$45 to ,56 1.32 (1.10–1.58)
$56 2.50 (2.13–2.93)
Duration of diabetes (years) (ref. ,5) * † *
$5 to ,10 1.11 (0.92–1.35)
$10 to ,15 1.59 (1.31–1.93)
$15 2.01 (1.69–2.38)
Treatment of diabetes (ref. oral medication only) † *
Diet or exercise 1.22 (0.97–1.55) 1.55 (1.15–2.10)
Oral medication plus insulin 1.39 (1.15–1.67) 1.08 (0.85–1.38)
Insulin only 2.05 (1.75–2.40) 1.13 (0.90–1.41)
BMI (kg/m2) (ref. $25 to ,30) † *
,25 1.43 (1.19–1.71) 1.09 (0.86–1.38)
$30 to ,35 0.94 (0.79–1.11) 1.08 (0.88–1.32)
$35 0.77 (0.64–0.92) 0.96 (0.76–1.22)
Smoking 1.26 (1.08–1.47) 1.62 (1.32–1.99) 1.74 (1.42–2.14) 0.6533
Systolic blood pressure (mmHg) (ref. ,130) † *
$130 to ,140 0.91 (0.76–1.10) 0.99 (0.79–1.23)
$140 1.21 (1.04–1.40) 0.94 (0.78–1.14)
LDL cholesterol (mg/dL) (ref. ,100)
$100 to ,130 0.76 (0.64–0.90) 0.94 (0.78–1.13) † *
$130 to ,160 0.79 (0.64–0.98) 0.98 (0.77–1.23)
$160 0.84 (0.63–1.11) 1.18 (0.87–1.61)
HbA1c (%) (ref. ,7) † *
$7 to ,8 1.05 (0.89–1.24) 1.17 (0.95–1.43)
$8 to ,9 0.95 (0.78–1.15) 1.09 (0.85–1.38)
$9 0.80 (0.67–0.97) 1.06 (0.84–1.35)
History of retinopathy 1.70 (1.46–1.97) 1.13 (0.92–1.38) † *
History of nephropathy 1.85 (1.60–2.13) 1.49 (1.20–1.84) 1.38 (1.14–1.67) 0.1208
History of microalbuminuria 0.95 (0.78–1.15) 0.82 (0.65–1.09) † *
History of diabetic peripheral neuropathy 1.74 (1.50–2.02) 1.02 (0.83–1.24) † *
History of hypertension 1.46 (1.25–1.70) 1.03 (0.81–1.32) † *
History of dyslipidemia 0.83 (0.73–0.94) 0.87 (0.71–1.06) † *
Continued on p. 1308
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cardiovascular, and noncardiovascular
mortality. Charlson Index is not associated
with cardiovascular mortality, and history
of macrovascular disease is not associated
with noncardiovascular mortality.
To our surprise, we found that history
of dyslipidemia is associated with a de-
creased risk of all-cause and cardiovascu-
lar mortality. We hypothesize that this
might be related to our inclusion of
dyslipidemia and LDL cholesterol levels
and use of cholesterol-lowering me-
dications in the models. If history of
dyslipidemia is an indicator of cholesterol-
lowering medication use, this would tend
to attenuate the association between dys-
lipidemia and mortality. Confounding by
indication might also explain the associa-
tions between antihypertensive medica-
tion use and cardiovascular mortality.
Higher rates of mortality are observed for
those using diuretics, b-blockers, and
other antihypertensive medications but
those medications are more likely pre-
scribed for those with longer duration
and more severe hypertension and for
those with cardiovascular disease and con-
gestive heart failure.
A previous study predicting all-cause
mortality in people with diabetes was
performed for 33,067 individuals in-
cluded in the Cleveland Clinic electronic
health record (14). This study only in-
cluded patients initially prescribed a single
oral hypoglycemic agent, whereas our
study included all people identiﬁed as
having type 2 diabetes regardless of med-
ication use. Both studies found that older
age, male sex, white race, smoking, insulin
use, history of heart disease, history of
heart failure, and not using aspirin predic-
ted greater risk of death. However, our
study did not assess glomerular ﬁltration
rate, oral diabetes medication class, dia-
stolic blood pressure, HDL, triglycerides,
new diagnosis of diabetes, or clopidogrel
use. We include an indicator for history of
diabetic nephropathy, which was signiﬁ-
cant in the most parsimonious model. Al-
though we included BMI, HbA1c, systolic
blood pressure, LDL, ACE inhibitor or
ARB use, and use of lipid-lowering drugs
as possible variables, none of these entered
the most parsimonious models.
Our ﬁndings were also similar to the
results of a study conducted inHongKong.
In that study, older age, male sex, history
of peripheral vascular disease, and insulin
use were associated with higher risk of all-
cause mortality (15). We allowed for a
continuous measurement of HbA1c and
BMI in our model but neither was signif-
icant in multivariate analyses. Our study
did not investigate albumin-creatinine ra-
tio or glomerular ﬁltration rate, although
we did include history of microalbuminu-
ria, nephropathy, and Charlson Index,
two of which were signiﬁcant in the
most parsimonious models. The measures
of area under the curve, sensitivity, and
speciﬁcity for our prediction equation
were very similar to those for the equation
developed in the Hong Kong study.
Our study has several limitations. First,
we sought to develop prediction equations
to optimally discriminate the outcome of
interest (mortality). As a result, we did not
seek to develop causal models. The fact
that a variable enters an equation does not
mean that it is causally important. Simi-
larly, variables that do not enter an equa-
tion are not necessarily unimportant in the
chain of causation. We conducted a sen-
sitivity analysis and found that stepwise
selection and backward elimination mod-
els align well. For all-cause mortality, 14
of the 17 variables were the same in the
stepwise and backward elimination mod-
els. For the cardiovascular mortality model,
all the signiﬁcant variables were the same.
Table 3dContinued
Characteristic
Unadjusted HR
(95% CI)
Fully adjusted HR
(95% CI)
Stepwise HR
(95% CI)
Estimated
regression
coefﬁcient
History of congestive heart failure 3.61 (3.09–4.21) 1.47 (1.18–1.84) 1.51 (1.22–1.87) 0.4157
History of TIA, stroke, or endarterectomy 2.27 (1.91–2.71) 1.11 (0.88–1.40) † *
History of angina, myocardial infarction,
other coronary heart disease, coronary
angioplasty, or coronary bypass 2.11 (1.85–2.40) 1.14 (0.94–1.39) † *
History of peripheral vascular disease
or peripheral vascular surgery 2.45 (2.07–2.90) 1.21 (0.97–1.50) † *
Current medication use
Aspirin 1.14 (0.99–1.31) 0.76 (0.63–0.91) † *
ACE inhibitors 1.21 (1.06–1.37) 1.02 (0.85–1.22) † *
ARB 1.10 (0.89–1.35) 1.06 (0.81–1.38) † *
b-Blocker 1.63 (1.42–1.88) 1.07 (0.89–1.30) † *
Calcium channel blocker 1.64 (1.43–1.88) 1.20 (1.00–1.44) † *
Other antihypertensive medication 1.68 (1.37–2.06) 1.02 (0.79–1.33) † *
Diuretic 2.19 (1.93–2.48) 1.36 (1.13–1.64) 1.37 (1.15–1.63) 0.4337
Statin 1.04 (0.91–1.18) 0.91 (0.75–1.11) † *
Other anticholesterol medication 1.07 (0.83–1.39) 1.06 (0.77–1.46) † *
Charlson Index * * 1.22 (1.18–1.27) 0.3027
Charlson Index (ref. ,1) * *
$1 to ,2 1.95 (1.00–3.82) 3.08 (1.23–7.69)
$2 to ,3 3.27 (1.68–6.36) 3.61 (1.44–9.03)
$4 8.77 (4.55–16.93) 6.25 (2.50–15.63)
P = 1(1+e2X), where X = data included in the table; ref., reference. The estimates given in the last column are for calculating the probability of death over 8 years. *Not
included in the model. †Did not enter stepwise regression because P value .0.05. Boldface values represent signiﬁcant at P , 0.05.
1308 DIABETES CARE, VOLUME 35, JUNE 2012 care.diabetesjournals.org
Risk factors for mortality in TRIAD
For the noncardiovascular mortality model,
8 of the 13 variables were the same. It is not
surprising that the noncardiovascular dis-
ease model did not align as well as the
others because many different risk factors
may contribute to mortality related to
cancer, infections, etc.
Another limitation of our study is the
use of data frompeople enrolled inmanaged
care plans; our results may not be general-
izable to those outside of managed care, or
even those in managed care plans with
different levels of access to care or quality of
care. Indeed, the fact that our population
had good access to high-quality care may
have attenuated the impact of biological
risk factors on mortality. In addition, our
sample did not include people with newly
diagnosed diabetes. Everyone had physi-
cian-diagnosed diabetes for at least 18
months before the survey, which might
have resulted in higher mortality rates.
In conclusion, we created three pre-
diction equations with good discrimina-
tion and high sensitivity and speciﬁcity.
Although our equations need to be vali-
dated in other populations, they highlight
the importance of speciﬁc demographic
and biological risk factors for mortality in
people with type 2 diabetes and provide
a quantitative assessment of risk. These
prediction equations may be incorporated
into computer simulation models of dis-
ease progression. After further validation,
clinicians may also use such equations to
inform patients about their risk for mor-
tality and to target the most modiﬁable
risk factors for intervention.
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